MAP2K7 and cancer: We have previously demonstrated synergy between PARP and MEK inhibitors in lines with an activated RAS/MAPK pathway and for PARP and PI3K pathway inhibitors in cancer patients consistent with the concept that targeting adaptive responses could be effective [27, 44, 45].